Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.
say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.poised for traditional U.S. approval
Lecanemab works by removing sticky clumps of the protein amyloid beta from the brain believed to be a hallmark of Alzheimer's. Nearly 13% of patients treated with the drug in the trial experienced potentially serious brain swelling. There are an estimated 7 million people in Europe with Alzheimer’s, a number expected to double by 2030, according to the European Brain Council.
Barclays analysts have forecast Europe sales will pick up pace overtime and peak in 2032 at about 13% of the patient population. It forecast sales of $2.6 billion in Europe versus $3.7 billion in the U.S. that year. Professor Giovanni Frisoni, director of a memory clinic in Geneva that sees about 900 patients a year, suggested the drug's impact would likely underwhelm patients.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA paves way for full approval of new Alzheimer's drugA panel of Food and Drug Administration advisers on Friday unanimously endorsed an experimental Alzheimer's drug that's been shown to have modest success slowing the progression of the disease, clearing a hurdle for full agency approval.
Read more »
New Hope in Alzheimer’s Fight: Addressing Myelin Degradation Could Prevent DiseaseNew research has demonstrated that impaired myelin actively promotes disease-related changes in Alzheimer’s disease. Alzheimer's disease, an irreversible e type of dementia, is the most prevalent neurodegenerative disease globally. Age is the predominant risk factor for this disease, but the reason
Read more »
FDA Panel Unanimously Endorses Lecanemab for Alzheimer'sFDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drug's clinical benefit for patients with Alzheimer's disease.
Read more »
European leaders offer more aid to Tunisia amid efforts to curb migrationEuropean leaders visiting Tunisia held out the promise of more than 1 billion euros in financial aid as well as investments in undersea data cables and renewable energy Sunday in an effort to restore stability to the North African country - and to stem migration from its shores to Europe.
Read more »
Vivendi’s Media & Entertainment Empire Set For Major Expansion As European Commission Approves Lagardère AcquisitionThe European Commission has given the greenlight for French conglom Vivendi’s acquisition of the Lagardère Group. The acquisition will make the Paris-based group one of the biggest media and entert…
Read more »
European leaders offer more aid to Tunisia amid efforts to curb migrationBy BOUAZZA BEN BOUAZZA and ANGELA CHARLTON (Associated Press) TUNIS, Tunisia (AP) — European leaders visiting Tunisia on Sunday held out the promise of more than 1 billion euros in financial …
Read more »